Related Experiment Videos
[Methods for evaluating biological response modifiers]
1Service d'hématologie clinique, Hôtel-Dieu, CHU de Nantes, 1, place Alexis-Ricordeau, 44035 Nantes.
Abstract:
Biological response modifiers (BRM) are a new approach of cancer treatment. The guidelines for their evaluation are comparable to those used for evaluating conventional anticancer treatments. However, it is more difficult to assess their efficacy and toxicity because of their own properties and of the characteristics of underlying diseases. The objectives of studying BRM efficacy are the following : 1- to confirm the pharmacodynamic effect observed in experimental models; 2- to assess the benefit for the patient. Phase II studies can occasionally be performed in healthy volunteers. Efficacy criteria are objective response rate, progression free survival, overall survival or, for hematopoietic growth factors, more specific criteria. In randomized phase III studies patients in the control arm can be observed without treatment, or receive a placebo or a standard treatment. As regards toxicity, side effects specifically related to the use of BRM are the synthesis of cytokines, the stimulation of immune system, the stimulation of tumor growth, the synthesis of anti-mouse of anti-BRM antibodies.
Insights
Biological response modifiers (BRMs) offer a novel cancer treatment approach. Evaluating BRM efficacy and toxicity presents unique challenges due to their properties and disease complexities.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Context:
- Biological response modifiers (BRMs) represent a novel therapeutic strategy in cancer treatment.
- Evaluating BRMs requires adapting methodologies used for conventional anticancer agents.
- BRM assessment is complicated by their unique properties and the nature of the diseases they target.
Purpose:
- To validate pharmacodynamic effects observed in preclinical models.
- To determine the clinical benefit of BRMs for cancer patients.
- To establish efficacy criteria including objective response rate, progression-free survival, and overall survival.
Summary:
- Phase II studies may involve healthy volunteers to assess BRM effects.
- Phase III trials compare BRMs against observation, placebo, or standard treatments.
- Toxicity evaluation includes BRM-specific side effects like cytokine synthesis and immune stimulation.
Impact:
- Provides a framework for evaluating novel cancer therapeutics.
- Highlights the complexities in assessing biological response modifiers.
- Informs clinical trial design and patient management strategies for BRM therapies.